Automated Image-based Biomarker Computation Tools for Diabetic Retinopathy

Information

  • Research Project
  • 9104250
  • ApplicationId
    9104250
  • Core Project Number
    R42TR000377
  • Full Project Number
    5R42TR000377-04
  • Serial Number
    000377
  • FOA Number
    PA-13-235
  • Sub Project Id
  • Project Start Date
    9/1/2012 - 12 years ago
  • Project End Date
    6/30/2017 - 7 years ago
  • Program Officer Name
    WILSON, TODD
  • Budget Start Date
    7/1/2016 - 8 years ago
  • Budget End Date
    6/30/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    04
  • Suffix
  • Award Notice Date
    6/23/2016 - 8 years ago
Organizations

Automated Image-based Biomarker Computation Tools for Diabetic Retinopathy

DESCRIPTION (provided by applicant): In this STTR project, we present EyeMark, a set of advanced image analysis tools for automated computation of biomarkers for diabetic retinopathy (DR) using retinal fundus images. Specifically, we will develop tools for computation of microaneurysm (MA) appearance and disappearance rates (jointly known as turnover rates) for use as a biomarker in quantifying DR progression risk. The availability of a reliable image-based biomarker will have high positive influence on various aspects of DR care, including screening, monitoring progression, drug discovery and clinical research. Measuring MA turnover involves two labor intensive steps: careful alignment of current and baseline images, and marking of individual MAs. This process is very time consuming and prone to error, if done entirely by human graders. The primary goal of this project is to overcome these limitations by automating both the steps involved in MA turnover measurement: accurate image registration, and MA detection. In Phase I we have designed and developed a MA turnover computation prototype tool that robustly registers longitudinal images (even with multiple lesion changes) and effectively detects MAs (lesion level AUROC=0.92). The tool provides graceful degradation to confounding image factors by reporting MA turnover as a range, thereby capturing the inherent confidence in MA detection. By the end of Phase II we will develop a clinically validated end-to-end desktop software for robust, automated computation of MA turnover biomarker, that can work on the cloud to produces results in near constant time (for large datasets), and also provide intuitive visualization tools for clinicians to more effectively monitor DR progression.

IC Name
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
  • Activity
    R42
  • Administering IC
    TR
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    483375
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    350
  • Ed Inst. Type
  • Funding ICs
    NCATS:483375\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    EYENUK, INC.
  • Organization Department
  • Organization DUNS
    832930569
  • Organization City
    WOODLAND HILLS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    913677409
  • Organization District
    UNITED STATES